← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV24행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
Ethanol (Ethanol)
Shi wei, MM·Chronic Myeloproliferative Disorde…
61 trials
Overview
Program
Ethanol
Overview
Company
Shi wei, MM
Overview
Modality
CGT
Overview
Target
Chronic Myeloproliferative Disorders
Overview
Indication
Chronic Myeloproliferative Disorders; Infection
Overview
Phase
PHASE_2
Overview
Status
DISCONTINUED
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Mechanism
targets were significantly enriched in the PI3K/AKT signaling pathway
MoA
Biomarker
biomarker study to explore early disease severity indicators
PK/PD
Species
Rat
PK/PD
Animal (cat.)
Rat
PK/PD
Experiment
Pharmacokinetic
Toxicology
Species
Rat
Toxicology
Animal (cat.)
Rat
Toxicology
Major finding
hepatotoxic risks might be linked to specific extraction methods and chemotypes
Clinical
Safety signal
hepatotoxic risks might be linked to specific extraction methods and chemotypes
Clinical
Selected reported efficacy
90%
Clinical
Result source
ClinicalTrials.gov NCT02335983
Clinical
Program phase
PHASE_2
Clinical
Trial ref
NCT02335983